Acidic tumor microenvironment abrogates the efficacy of mTORC1 inhibitors

被引:49
|
作者
Faes, Seraina [1 ,2 ]
Duval, Adrian P. [1 ,2 ,6 ]
Planche, Anne [1 ,2 ]
Uldry, Emilie [1 ,2 ]
Santoro, Tania [1 ,2 ]
Pythoud, Catherine [1 ,2 ]
Stehle, Jean-Christophe [3 ,4 ]
Horlbeck, Janine [3 ,4 ]
Letovanec, Igor [4 ,5 ]
Riggi, Nicolo [4 ,5 ]
Demartines, Nicolas [1 ,2 ]
Dormond, Olivier [1 ,2 ]
机构
[1] CHU Vaudois, Lausanne Univ Hosp, Pavillon 4,Av Beaumont, CH-1011 Lausanne, Switzerland
[2] Univ Lausanne, Pavillon 4,Av Beaumont, CH-1011 Lausanne, Switzerland
[3] CHU Vaudois, Univ Lausanne Hosp, Mouse Pathol Facil, Lausanne, Switzerland
[4] Univ Lausanne, Lausanne, Switzerland
[5] CHU Vaudois, Univ Lausanne Hosp, Inst Pathol, Lausanne, Switzerland
[6] Ecole Polytech Fed Lausanne, Swiss Fed Inst Lausanne, Swiss Inst Expt Canc Res ISREC, Lausanne, Switzerland
基金
瑞士国家科学基金会;
关键词
Tumor Microenvironment; Acidity; mTORC1; Rapamycin; Sodium Bicarbonate; Resistance Mechanisms; SODIUM-BICARBONATE; SYSTEMIC BUFFERS; CELL-GROWTH; PH; ACIDOSIS; PHOSPHORYLATION; CARCINOGENESIS; EVEROLIMUS; RESISTANCE; CARCINOMA;
D O I
10.1186/s12943-016-0562-y
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Blocking the mechanistic target of rapamycin complex-1 (mTORC1) with chemical inhibitors such as rapamycin has shown limited clinical efficacy in cancer. The tumor microenvironment is characterized by an acidic pH which interferes with cancer therapies. The consequences of acidity on the anti-cancer efficacy of mTORC1 inhibitors have not been characterized and are thus the focus of our study. Methods: Cancer cell lines were treated with rapamycin in acidic or physiological conditions and cell proliferation was investigated. The effect of acidity on mTORC1 activity was determined by Western blot. The anticancer efficacy of rapamycin in combination with sodium bicarbonate to increase the intratumoral pH was tested in two different mouse models and compared to rapamycin treatment alone. Histological analysis was performed on tumor samples to evaluate proliferation, apoptosis and necrosis. Results: Exposing cancer cells to acidic pH in vitro significantly reduced the anti-proliferative effect of rapamycin. At the molecular level, acidity significantly decreased mTORC1 activity, suggesting that cancer cell proliferation is independent of mTORC1 in acidic conditions. In contrast, the activation of mitogen-activated protein kinase (MAPK) or AKT were not affected by acidity, and blocking MAPK or AKT with a chemical inhibitor maintained an anti-proliferative effect at low pH. In tumor mouse models, the use of sodium bicarbonate increased mTORC1 activity in cancer cells and potentiated the anti-cancer efficacy of rapamycin. Combining sodium bicarbonate with rapamycin resulted in increased tumor necrosis, increased cancer cell apoptosis and decreased cancer cell proliferation as compared to single treatment. Conclusions: Taken together, these results emphasize the inefficacy of mTORC1 inhibitors in acidic conditions. They further highlight the potential of combining sodium bicarbonate with mTORC1 inhibitors to improve their anti-tumoral efficacy.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] AZD2014, a dual mTORC1 and mTORC2 inhibitor is differentiated from allosteric inhibitors of mTORC1 in ER+ breast cancer
    Guichard, Sylvie M.
    Howard, Zoe
    Heathcote, Dan
    Roth, Mark
    Hughes, Gareth
    Curwen, Jon
    Yates, James
    Logie, Armelle
    Holt, Sarah
    Chresta, Christine M.
    Davies, Barry R.
    Malagu, Karine
    Hummersone, Marc
    Pass, Sarah L.
    Green, Stephen
    Pass, Martin
    CANCER RESEARCH, 2012, 72
  • [22] Imidazo[1,5-a]pyrazines: Orally efficacious inhibitors of mTORC1 and mTORC2
    Crew, Andrew P.
    Bhagwat, Shripad V.
    Dong, Hanqing
    Bittner, Mark A.
    Chan, Anna
    Chen, Xin
    Coate, Heather
    Cooke, Andrew
    Gokhale, Prafulla C.
    Honda, Ayako
    Jin, Meizhong
    Kahler, Jennifer
    Mantis, Christine
    Mulvihill, Mark J.
    Tavares-Greco, Paula A.
    Volk, Brian
    Wang, Jing
    Werner, Douglas S.
    Arnold, Lee D.
    Pachter, Jonathan A.
    Wild, Robert
    Gibson, Neil W.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (07) : 2092 - 2097
  • [23] Iron chelation inhibits mTORC1 signaling in tumor cells
    Shang, Chaowei
    Zhou, Hongyu
    Huang, Shile
    CANCER RESEARCH, 2016, 76
  • [24] mTORC1 Status Dictates Tumor Response to Targeted Therapeutics
    Kelsey, Ilana
    Manning, Brendan D.
    SCIENCE SIGNALING, 2013, 6 (294)
  • [25] Dihydroartemisinin inhibits mTORC1 signaling in tumor cells.
    Odaka, Yoshinobu
    Xu, Baoshan
    Huang, Shile
    CANCER RESEARCH, 2013, 73 (08)
  • [26] FilGAP regulates tumor growth in Glioma through the regulation of mTORC1 and mTORC2
    Tsutsumi, Koji
    Nohara, Ayumi
    Tanaka, Taiki
    Murano, Moe
    Miyagaki, Yurina
    Ohta, Yasutaka
    SCIENTIFIC REPORTS, 2023, 13 (01):
  • [27] FilGAP regulates tumor growth in Glioma through the regulation of mTORC1 and mTORC2
    Koji Tsutsumi
    Ayumi Nohara
    Taiki Tanaka
    Moe Murano
    Yurina Miyagaki
    Yasutaka Ohta
    Scientific Reports, 13 (1)
  • [28] Bi-Steric mTORC1-Selective Inhibitors Demonstrate Improved Potency and Anti-Tumor Activity in Lung Diseases with mTORC1 Hyperactivation
    Du, H.
    Yang, Y.
    Liu, H.
    Singh, M.
    Kwiatkowski, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [29] mTORC1 pathway disruption abrogates the effects of the ciliary neurotrophic factor on energy balance and hypothalamic neuroinflammation
    Andre, Caroline
    Catania, Caterina
    Remus-Borel, Julie
    Ladeveze, Elodie
    Leste-Lasserre, Thierry
    Mazier, Wilfrid
    Binder, Elke
    Gonzales, Delphine
    Clark, Samantha
    Guzman-Quevedo, Omar
    Abrous, Djoher Nora
    Laye, Sophie
    Cota, Daniela
    BRAIN BEHAVIOR AND IMMUNITY, 2018, 70 : 325 - 334
  • [30] mTORc1 but not JNK Inhibition Augments Glucocorticosteroid Efficacy in Multiple Sclerosis
    Hoepner, Robert
    Bagnoud, Maud
    Pistor, Maximilian
    Salmen, Anke
    Briner, Myriam
    Schrewe, Lisa
    Guse, Kirsten
    Ahmadi, Farhad
    Demir, Seray
    Laverick, Louise
    Gresle, Melissa
    Worley, Paul
    Reichardt, Holger
    Butzkueven, Helmut
    Gold, Ralf
    Luehder, Fred
    Chan, Andrew
    NEUROLOGY, 2019, 92 (15)